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Background and Objective. The key pathogenic fea-
ture of TTP is the formation of platelet aggregates
within the microcirculation; however, the etiology of
such aggregates has been elusive for years. A large
amount of evidence points to an abnormal interaction
between damaged vascular endothelium and platelets,
although the cause of the primary microvascular
endothelial cell injury is seldom clear. The autoimmune
hypothesis often recurs, and this is based on a num-
ber of observations: the claimed superiority of plasma-
exchange over plasma infusion, the anecdotal report
of the presence of immunocomplexes and autoanti-
bodies in TTP patients, the efficacy of the administra-
tion of corticosteroids and other immunosuppressant
agents, and the concomitant occurrence of TTP in
association with autoimmune diseases, especially sys-
temic lupus erythematosus (SLE). This review will
focus on the complex relationships between TTP and
humoral autoimmunity; in particular, similarities and
differences between TTP, SLE and antiphospholipid
(aPL) antibodies syndrome, as well as the putative
role of several other antibodies directed towards
endothelial cells and/or platelets, including the
recently discovered anti-CD36 antibodies and antivWF-
cleaving metalloprotease, will be discussed.
Design and Methods. The authors have been involved
in the study and treatment of TTP and autoimmune
diseases for years; furthermore, the PubMed data base
of the National Library of Congress has been exten-
sively searched using the Internet.
Conclusions. Although over the years evidence has
increased in favor of the autoimmune hypothesis for
TTP etiopathogenesis, TTP should not yet be consid-
ered an autoimmune disease. Autoantibodies should
be regarded as only one of the many different insults
which can trigger microvascular thrombosis even
though the autoimmune theory of the pathogenesis of
TTP is gaining more and more strength. As far as con-
cerns the relationship between TTP, SLE and aPL anti-
bodies-related disorders, these diseases should be dis-
tinguished on the basis of both different clinical pre-
sentations and accurate antibody screening, although
this approach should definitely not delay the prompt
start of treatment.
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Thrombotic thrombocytopenic purpura (TTP) is arare hematologic syndrome first described in 1924by Eli Moschowitz who used the term acute
pleiochromic anemia with hyaline thrombosis of terminal arteri-
oles and capillaries.1 It was Karl Singer, however, who intro-
duced the term TTP, more than twenty years later.2
Nowadays, TTP is estimated to occur in about 1
case per million people,3 with a preference for young
women in their thirties; however, over the past
decade, the incidence of TTP appears to have
increased,4 presumably due to heightened awareness
of the syndrome. An occlusive microangiopathy pref-
erentially localized to terminal arterioles and capil-
laries (but not usually venules) in the whole body
causes the clinical manifestations of TTP, i.e., the
presence of microangiopathic schistocytic hemolytic
anemia, consumption thrombocytopenia causing
severe hemorrhagic diathesis, fluctuating central ner-
vous system abnormalities, fever and renal impair-
ment of different degrees.1
However, the classic pentad of symptoms
described above is observed in only about 40% of
TTP patients, with renal symptoms being observed in
as few as 38% of patients in our country,5 while the
triad of anemia, thrombocytopenia and bizarre neu-
rologic abnormalities can be observed in up to 75%
of patients.3 It has, therefore, been proposed that
TTP should be redefined as a syndrome of Coombs’
negative microangiopathic hemolytic anemia and
thrombocytopenia in the absence of other possible
causes of these manifestations.6,7
The key pathogenic feature of TTP is the formation
of platelet aggregates; however, the etiology of such
aggregates has been elusive and controversial for
years. Several recent studies point to abnormal inter-
action between damaged vascular endothelium and
platelets,8 although other investigators found differ-
ent platelet aggregating plasma proteins of the fam-
ily of cysteine proteinases,9,10 at times thought to be
cathepsin-L10,11 or calpain.12 As a matter of fact, the
hypothesis of endothelial damage is supported by
several experimental findings: abnormal production
and metabolism of von Willebrand factor (vWF) mul-
timers, with ultra-large vWF multimers, capable of
increasing platelet adhesiveness in vitro, shed into the
circulation by endothelial cells,13 reduced vascular
prostacyclin (PGI2) production,14 impaired fibri-
nolytic activity,15 increased vascular endothelial cell
markers in blood,16 and pro-apoptotic effects of TTP
plasma on microvascular endothelial cells in vitro.17
Despite the presence of a number of ill-defined sec-
ondary TTP (or thrombotic microangiopathies if one
also include the closely-related hemolytic uremic syn-
drome, HUS) (Table 1), the cause of the primary
microvascular endothelial cell injury is seldom clear,
especially in the vast majority of TTP cases, the idio-
pathic ones. An autoimmune hypothesis explaining
the primary cause of endothelial damage often
recurs.18 The hypothesis is based on many observa-
tions: a) the superiority of plasma-exchange over plas-
ma infusion in the treatment of TTP7 – although still
debated by some authors – suggests the possibility
that removing a possible humoral pathogenetic factor
may be more effective than administering a possibly
lacking factor;19 b) immunocomplexes and several
autoantibodies were anecdotally reported as patho-
genetic factors in TTP;20-24 c) some TTP patients seem
to be cured by the administration of corticosteroids24
and other immunosuppressant agents such as vin-
cristine,25 cyclophosphamide,26 azathioprine;27 d) TTP
may occur in association with autoimmune diseases,
especially systemic lupus erythematosus (SLE)
(reviewed in ref. #28) and the differential diagnosis
between TTP and SLE is particularly difficult.
This review will focus on the complex relationships
between TTP and humoral autoimmunity; in particu-
lar, similarities and differences between TTP, SLE and
antiphospholipid (aPL) antibodies syndrome, as well
as the putative role of several antibodies directed
towards endothelial cells, platelets, and/or plasma
proteases, will be discussed.
TTP, SLE, and antiphospholipid antibodies
Biological viewpoint
It is well known that SLE and related diseases may
present with recurrent thromboses and thrombocy-
topenia28 that are usually associated with aPL
autoantibodies detected by either lupus anticoagu-
lant test, false positive serologic tests for syphilis or
solid phase immunosorbent assay.29,30 aPL antibod-
ies bind to anionic phospholipids, such as phos-
phatidylserine, which are important constituents of
the platelet and cell membrane, even though, under
normal conditions, these are concentrated within the
inner leaflet of the phospholipid bilayer. aPL anti-
bodies are known to need a co-factor to bind to
platelets and to endothelial cells;31,32 most often this
is b2-glycoprotein-I (b2-GP-I),33,34 although pro-
thrombin, protein C and protein S are alternative tar-
gets of aPL antibodies.35 Shi et al.36 studied the effect
of aPL antibodies on platelet aggregation to physio-
logic stimuli without showing any major influence.
However, other investigators showed that mono-
clonal antibodies to b2-GP-I possess lupus anticoag-
ulant properties and strongly potentiated the platelet
aggregation response to adrenaline or ADP when b2-
GP-I was present.37 This effect was shown to be
dependent upon a secondary interaction of the Fc
fragment of the antibody with the platelet FcgRII
receptor, suggesting a platelet activation mechanism
comparable to that seen in heparin-induced throm-
bocytopenia.38
Since endothelium seems to play a key role in the
pathogenesis of both TTP and SLE, some attention
has recently been devoted to the endothelial pro-
duction of nitric oxide (NO) which, together with
PGI2 and lipoxygenase products, contributes to main-
taining normal endothelial non-thrombogenicity.
As a matter of fact, under normal conditions, the
shear stress-induced release of NO continuously
causes relaxation of vascular smooth muscle cells and
contributes to the prevention of platelet adhesion
and aggregation in normal blood vessels;39 further-
more, substances with strong vasoconstrictor prop-
erties (serotonin, ADP, thromboxane A2 and platelet
aggregating factor), secreted by aggregating throm-
bocytes, are potent releasers, through the interaction
with specific receptors on endothelial cells, of NO
which counteracts their action.40 In TTP and/or aPL
antibodies-related conditions, impaired NO release
might thus be postulated, as has already been
demonstrated to occur in pre-eclampsia,41 a condi-
tion in which endothelial cell damage plays a key role.
However, recent results seem to suggest that NO is
not implicated in the pathogenesis of these diseases,
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Table 1. Proposed, simplified classification of the thrombot-
ic microangiopathies (TTP and HUS).
TTP/HUS
Idiopathic
Malignancy-associated
Drug-associated: standard-dose chemotherapy 
agents;
high-dose chemotherapy agents 
given as induction within bone 
marrow transplantation procedures;
immunosuppressants given 
after transplantation;
estroprogestins;
D-penicillamine;
others;
Pregnancy and post-partum-associated
Autoimmune-associated: SLE;
RA;
Sjögren’s syndrome;
mixed connective tissue disease;
scleroderma;
adult onset Still’s disease;
polymyositis;
myasthenia gravis;
Infection-associated: enterotoxin-producing E-Coli strains;
others
since plasma concentrations of nitrates (a sensitive
index of NO production) identical to those of normal
healthy volunteers were titered in idiopathic TTP
patients, in aPL antibodies-positive and negative SLE
patients, and in primary aPL antibodies syndrome
patients.42,43
More in general, the occurrence of thromboses in
patients with autoimmune diseases appears to be
multifactorial, several mechanisms having been pro-
posed at times to contribute to the disruption of
homeostasis between the normal procoagulant and
anticoagulant pathways. The production of autoanti-
bodies that a) bind to coagulation factors or counter-
regulatory proteins, b) cause endothelial cell injury or
activation, c) bind directly to platelets, d) impair fib-
rinolysis, e) inhibit PGI2 production, or determine an
imbalance between PGI2/thromboxane  ratio,  may
act as triggering events for abnormal coagulation.28,29
Clinical viewpoint
Besides having in common possible pathogenetic
events, in particular, endothelial cell injury, TTP and
SLE also have several clinical findings in common -
i.e., fever, central nervous system symptoms, renal
disease and hemolytic anemia which is autoimmune
in SLE and microangiopathic in TTP (the hemato-
logic characteristics of TTP, SLE and primary aPL
antibodies syndrome are compared in Table 2); thus,
a patient with thrombotic thrombocytopenia plus
the above symptoms should be carefully examined to
differentiate between TTP and aPL antibodies-posi-
tive SLE.
Idiopathic TTP is usually not related to aPL; indeed,
even though some authors have made a diagnosis of
TTP even in the presence of aPL antibodies, our expe-
rience strongly supports the evidence that anticardi-
olipin antibodies and other SLE-related autoanti-
bodies, such as anti-b2-GP-I antibodies (Figure 1),
are absent in TTP patients.44,45
The possible, but rare, association between TTP
and SLE complicates the picture further.
To our knowledge, more than 30 cases of TTP
occurring in SLE patients have been reported in the
literature to date.28
An intriguing question is whether aPL antibodies
may have a role  in the development of TTP in SLE
patients. Several TTP cases have been reported in SLE
patients with positive aPL assay;46,47 furthermore, aPL
were found in a few cases of post-partum HUS.48 This
has led to the suggestion that these antibodies have
a pathogenic role in platelet aggregation and/or
endothelial damage causing TTP. However, as out-
lined before, our own experience clashes with this
viewpoint. Indeed, if we take into account that aPL
are present in up to 50% of SLE patients,49,50 a posi-
tive aPL assay could be expected in one half of
patients with SLE-associated TTP, independently of
any pathogenic role in the latter disorder.
Traditional estimates of the diagnosis of TTP in
SLE patients range from 1% to 4%,28,51 although post-
mortem examination of SLE patients suggests that this
association may be present in a significantly higher
percentage of SLE patients succumbing to multior-
gan system failure.52 In Italy, we first found 4 cases of
SLE (all aPL-negative) in 103 TTP patients gathered
by the Italian Cooperative Group for TTP – i.e. an
incidence of 3.8%,53 but the rate now appears even
lower – 2.28%, since no SLE cases were recorded in
72 more TTP patients enrolled in a national multi-
center trial.54
The diagnosis of SLE usually precedes that of TTP,
even though cases of TTP preceding or occurring
simultaneously with the diagnosis of SLE have also
been reported; TTP may present in clinically quiescent
SLE, or else complicate an active SLE.28 The different
pattern of association of the two diseases obviously
determines the optimal treatment approach; thus,
TTP episodes developing in quiescent SLE patients
should be treated as de novo TTP cases, while, in con-
comitant TTP and active SLE, treatment should be
directed at both conditions. Granted that plasma-
exchange (with or without antiplatelet drugs and/or
steroids) is the treatment of choice for TTP, corti-
costeroids with or without a second-line agent such
as cyclophosphamide, remain the treatment of
choice for active life-threatening SLE and should be
utilized along with plasma-exchange in the proper
clinical setting.
A procedure which may theoretically be useful to
treat this rare association is the perfusion of autolo-
gous plasma over filters containing staphylococcal
protein-A covalently bound to polyacrylamide beads.55
This treatment has already proved to be effective in
the treatment of TTP  induced by antineoplastic
drugs,56 another rare kind of secondary TTP.57
In conclusion, even though the concomitant pres-
ence of TTP, SLE and aPL antibodies in the same
patient is possible, there is no evidence, to date, that
aPL antibodies play any pathogenic role in TTP, even
in SLE patients.
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Table 2. Comparison of the hematologic characteristics of
TTP, SLE and primary aPL antibodies syndrome.
Hematologic TTP SLE Primary aPL 
characteristic syndrome
Thrombocytopenia consumptive immune- immune-
(microangiopathic) mediated mediated
Microangiopathic present absent absent
hemolytic anemia
Schistocytes present rare absent
aPL antibodies absent variable present at
high titer
TTP and other autoantibodies
Antineutrophil cytoplasmic antibodies (ANCA)
Several experimental data support the hypothesis
that neutrophils participate in the pathophysiology
of hemolytic-uremic syndrome (HUS),58-60 a syndrome
which shares so many similarities with TTP that many
authors consider TTP and HUS only qualitatively dif-
ferent expressions of a unique physiopathologic enti-
ty.14 Recently, Rollino et al. found the serum of one
HUS patient (of 4 tested) positive for both anti-pro-
teinase 3 (PR3-Abs, or C-ANCA) and anti-myelo-
peroxidase (MPO-Abs, or P-ANCA) antibodies and
thus hypothesized the participation of ANCA (which
can cause endothelial cell damage through different
mechanisms), together with anti-elastase antibodies,
in the pathophysiology of HUS, at least in certain
patients.61 Since it is theoretically possible that neu-
trophils could initiate, via ANCA-induced degranula-
tion and free radical production, the endothelial dam-
age that ultimately leads to the clinical pattern of
acute TTP, even without leaving any clear evidence of
their involvement behind, our Group tested the sera
from 29 acute phase TTP patients for the presence of
ANCA. The absence of ANCA in the sera of our
patients62 seems to exclude their involvement in the
pathogenesis of TTP. Moreover, even in HUS, the par-
ticipation of ANCA in the etiopathogenesis of this dis-
ease seems far from convincing, especially in the light
of an earlier study demonstrating the absence of
ANCA in the sera of 27 HUS patients.63 Furthermore,
the concomitant C-ANCA and P-ANCA positivity
reported by Rollino et al. in a single patient61 could be
a casual association, since vasculitis patients hardly
ever have both types of antibodies,64,65 as would be
expected if the autoantibody formation was a sec-
ondary phenomenon.
Anti-factor VIII antibodies
The case of a male patient with long-standing hairy
cell leukemia under interferon-a treatment who
developed anti-factor VIII antibodies and recurrent
TTP has been recently described.66 Despite the fact
that, to our knowledge, this is the only case of anti-
factor VIII antibodies in TTP reported to date in the
literature, some interesting observations may be
extrapolated from this patient.
Hairy cell leukemia has been associated with several
autoimmune phenomena, but never with TTP or with
the development of anti-factor VIII autoantibodies,
the latter being most often seen in patients with
hemophilia A treated with factor replacement thera-
py, or in otherwise healthy elderly subjects.56 Con-
versely, the development of a vast array of autoim-
mune phenomena and diseases may follow and com-
plicate interferon treatment;67 furthermore, interfer-
on-induced damage to microvascular endothelial
cells has been demonstrated in vivo.68
Even though the authors of this case report stressed
that the involvement of interferon-a in the develop-
ment of both anti-factor VIII antibodies and TTP
could only be postulated and not unquestionably
proved, this original report seems once again to high-
light the central role of endothelial damage in the
pathogenesis of TTP, while the nature of the anti-
bodies insulting microvascular endothelial integrity,
leading to TTP, seems less important.
Antiplatelet antibodies
Antiplatelet antibodies in TTP patients69-72 and,
more often, patients showing, at different times dur-
ing their clinical history, both ITP and TTP have been
described in the literature,72-77 and a case of con-
comitant TTP and autoimmune anemia has also
been reported.73 However, many of the above cases
could be (and have been) criticized, since the classic
criteria to diagnose TTP were seldom present, mean-
ing that the disease described might have been, in at
least some of the reported cases, simply Evans’ syn-
drome – i.e., the association of autoimmune anemia
and thrombocytopenia;78 even the microscopy obser-
vation of schistocytes in peripheral blood smears is
not sufficient in these cases, since subclinical ery-
throcyte fragmentation has been proved in nearly all
ITP patients.78,79 Currently, the established criteria to
diagnose TTP require the absence of other causes
responsible for both anemia and thrombocytope-
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Figure 1. Anti-b2-glycoprotein-I (anti-b2-GP-I) antibodies in
31 antiphospholipid antibodies-negative SLE (aPL– SLE), 22
antiphospholipid antibodies-positive (aPL+ SLE) SLE, 7 pri-
mary antiphospholipid syndrome (PAPS), and 10 thrombot-
ic thrombocytopenic purpura (TTP) patients. Anti b2-GP-I
antibodies were detected using a sensitive immunosorbant
assay, as described by Del Papa et al.31 The upper normal
limit was considered as the optical density (OD) mean val-
ue of 15 control subjects ± 3 standard deviations (SDs).
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nia,6,7,54 thus including antiplatelet antibodies. Unfor-
tunately, the present methodology used to measure
these antibodies is still affected by a high rate of false
negative and false positive results; therefore, the risk
of misdiagnosing a case of TTP because of the pres-
ence of false positive anti-platelet antibodies should
also be considered.
On the other hand, the presence of antiplatelet
antibodies cannot be used, per se, to rule out SLE or
aPL antibodies-related conditions; as a matter of
fact, a French group has recently suggested that anti-
bodies directed against major platelet membrane gly-
coproteins, such as glycoprotein IIb-IIIa and glyco-
protein Ib-IX, are present in a great number of
patients with SLE and primary aPL antibodies syn-
drome,80 probably playing a role in the development
of the thrombocytopenia observed in the above dis-
eases.
Anti-endothelial cell antibodies
The hypothesis of endothelial cell injury by anti-
endothelial cell antibodies in TTP patients, leading to
the overt syndrome, dates back to 1988, when Leung
et al. demonstrated these antibodies, both of the IgG
and IgM types, in 3 of 5 adult TTP patients and in 13
of 14 children with the classic – i.e., pediatric, HUS.21
Since immunofluorescence, ELISA, and complement-
fixation techniques might fail to detect antibodies
against antigenic sites which are either inaccessible or
not displayed in recognizable cellular structures,
Koenig et al. subsequently demonstrated, using West-
ern blot analysis, some antibodies binding to human
renal microvascular cell proteins. The most impor-
tant antigen was a 43 KDa one, found in 13 of 14
and 4 of 5 TTP and HUS patients, respectively;22 sub-
cellular fractionation localized these antigens to
cytosolic and nuclear compartments,22 thus con-
firming the initial hypothesis. Unfortunately, to our
knowledge, this interesting research vein has not been
exploited further.  
Anti-CD36 antibodies
More recently, much experimental attention has
been devoted to CD36 (also known as glycoprotein IV
[gpIV]), a membrane antigen occurring in platelets,
endothelial cells, reticulocytes, monocytes, and other
cells and tissues.81,82 Interestingly, CD36 expression in
endothelial cells is characteristically restricted to cap-
illary endothelial cells and is not seen in the endothe-
lia of large vessels;83,84 furthermore, monoclonal anti-
bodies directed against CD36 have been demonstrat-
ed to induce platelet activation85 and, most impor-
tant, this glycoprotein has already been demonstrat-
ed to be the receptor of p37, a platelet agglutinating
protein86,87 previously isolated and purified from the
plasma of TTP patients.88,89
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Figure 2. TTP is currently considered as the clinical result of an abnormal interaction between microvascular endothelium and
platelets. As shown in this picture, several autoantibodies may interact with microvascular endothelial cells (MVECs), platelets
and/or the vWF-cleaving proteases, leading alternatively to a primary endothelial damage followed by enhanced platelet aggrega-
tion, or to an enhanced platelet aggregation, followed by subsequent endothelial damage. 
ULvWF: ultra-large vWF multimers; P: vWF-cleaving metalloproteases.
In 1994, using an accurate and elegant experimen-
tal design, Tandon et al. demonstrated that antibod-
ies directed against CD36 occur in about 80% of TTP
patients.23 The authors reasoned that these antibod-
ies might be part of a spectrum of autoantibodies
arising from immune system hyperactivity or in
response to membrane changes in TTP patients, leav-
ing the fundamental question open: is it the endothe-
lial cell damage (in this case due to an autoimmune
reaction) leading to abnormal platelet aggregation,
or a primary platelet aggregation causing endothelial
damage and consequently an autoimmune response
directed against endothelial cell antigen (Figure 2),
which is central in TTP etiopathogenesis?
Interestingly, more and more pieces of evidence
suggest the involvement of anti-CD36 autoantibod-
ies in the pathogenesis of thrombotic complications
in patients with lupus anticoagulant but not SLE,90
active SLE with80 or without aPL antibodies,91 and
thrombotic complications with recurrent fetal loss
but neither SLE, nor aPL antibodies or TTP,92 which
further complicates the complex relationships
between SLE and TTP. However, these results should
be confirmed on larger case series for better charac-
terization of the specificity of CD36 antibodies in dif-
ferent diseases.
Breaking news: antibodies against von
Willebrand factor cleaving metallo-
protease
vWF, whose unusually large multimers were pro-
posed as the agglutinating substance responsible for
platelet aggregation under high intravascular shear
stress conditions in TTP patients,13 is secreted by
endothelial cells as an extra large polymer of a poly-
peptide joined by disulfide bonds.93 Subsequently, this
extra large polymer is physiologically cleaved in the cir-
culation between tyrosine at position 842 and methio-
nine at position 843 by a 200-Kd plasma metallopro-
tease into smaller, functionally low-adhesive dimers
of 176-Kd and 140-Kd, respectively.94-97
A severe deficiency of this protease was found in the
plasma of 4 patients with chronic relapsing TTP,98
while in another patient with recurrent TTP, both a
deficiency of protease activity and an autoantibody
against the same vWF-cleaving protease was
described.99
Very recently, Tsai and Lian in New York and Furlan
et al. in Switzerland, independently found little – if
any – plasma vWF-cleaving metalloprotease activity
during acute TTP episodes (with a return to baseline
values at disease recovery), together with an IgG
autoantibody directed against components of the
enzyme, which accounted for the above lack of met-
alloprotease activity;100,101 the above findings were
consistent between the two studies and were
observed on a significative number of TTP patients.
Furthermore, the study by Furlan et al.100 provide an
useful tool to distinguish TTP from HUS, an extreme-
ly controversial topic, especially between hematolo-
gists and nephrologists; indeed, TTP patients had lit-
tle or no vWF-cleaving metalloprotease activity in plas-
ma, whereas the enzyme was normal or nearly so in
patients considered to have familial or acquired
HUS,100 a finding which can also explain why PE ther-
apy, which is so effective in treating TTP patients, yields
disappointing results in patients with acquired HUS.102
These intriguing findings seem to add another – rel-
evant – brick in the construction of an autoimmune
theory for the pathogenesis of TTP, even though, as
stressed by Moake in his editorial accompanying the
metalloprotease papers, TTP is only less of a mystery,
but still a mystery.
TTP and other autoimmune diseases
Rare case reports have dealt with the association of
TTP with a vast array of autoimmune diseases, such
as rheumatoid arthritis, Sjögren’s syndrome, mixed
connective tissue disease, scleroderma, polymyositis,
adult onset Still’s disease, and myasthenia gravis.28
However, in some of the above cases, the develop-
ment of TTP may have been related to factors other
than the underlying autoimmune disease, such as
infections or medications;28 in particular, three of the
patients with TTP and rheumatoid arthritis devel-
oped TTP during D-penicillamine treatment for the
autoimmune disease.103-105 These TTP cases should,
therefore, be considered as drug-, and not autoim-
munity-related, since D-penicillamine, a drug char-
acterized by an impressive array of adverse reactions
including thrombocytopenia, leukopenia, bone mar-
row aplasia and renal function impairment, occa-
sionally also causes classic TTP,106 or TTP-like
episodes.107 Unfortunately, the biological mecha-
nisms underlying the development of TTP in each
autoimmune condition was not investigated in these
rare cases, so that the above reports are of anecdoc-
tal interest only.
Conclusions
The extreme rarity of TTP makes it difficult both to
perform clinical trials in these patients and to  study
the biological pathophysiology of the disease itself.
Indeed, basic research on TTP has been limited until
recently by the scarcity of both patients and biologi-
cal samples; furthermore, the aggressivenes of this
life-threatening disease often impels physicians to
start treatment immediately (frequently using corti-
costeroids), which may interfere with subsequent bio-
logical investigations. 
Even though over the years evidence has increased
in favor of the autoimmune hypothesis for the
etiopathogenesis of TTP, TTP should not yet be con-
sidered an autoimmune disease. Further insights into
the biology of anti-CD36 antibodies, and anti-vWF
cleaving protese, could radically change this point of
view in the future.
At present, autoantibodies should be regarded as
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only one of the many different insults which can cause
endothelial damage or abnormal platelet aggregation,
thus triggering microvascular thrombosis with all its
consequences - i.e., platelet consumption leading to
hemorrhagic diathesis, erythrocyte fragmentation with
consequent anemia, thrombotic and/or ischemic
complications in different organs or tissues.
As already stressed within this review, TTP, SLE and
aPL antibodies-related disorders should be distin-
guished on the basis of both different clinical pre-
sentation (through an accurate search for common-
ly accepted diagnostic criteria for one or other con-
dition) and on the basis of accurate antibody screen-
ing; thus, we believe that the presence of aPL autoan-
tibodies should give evidence against a diagnosis of
TTP; however, this is clearly not a categorical state-
ment, since we cannot exclude that aPL antibodies
may, in a minority of patients, be associated with a
primary endothelial damage ultimately resulting in
overt TTP.
Despite the undoubted and repeatedly stressed
utility of accurate antibody screening emerging from
this review, if a patient presents with the clinical tri-
ad (or indeed the classic pentad) of symptoms and
signs suggestive of TTP, it would certainly be consid-
ered malpractice not to start plasma-exchange as
soon as technically possible; indeed, if one was to
wait for antibody titers to return (which could take
days in some institutions) to confirm or exclude the
diagnosis of TTP, mortality rates would return to the
dismal rates noted before the institution of plasma-
exchange therapy. A prompt execution of plasma-
exchange has been demonstrated to be a key element
in determining treatment success.5
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